Byron Lam: Clinical Trials

2 trials sponsored by Byron Lam, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed. 1 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 11Completed 1
Phase 21Completed 1

Follow Byron Lam: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Choroideremia Gene Therapy Clinical Trial
Injection of AAV2-REP1 (10e11 vg) - Choroideremia
Phase 2CompletedByron Lam62015-09-012019-07-29
Safety Study of an Adeno-associated Virus Vector for Gene Therapy of Leber's Hereditary Optic Neuropathy
injection of scAAV2-P1ND4v2 1.18x10e9 vg (Low),, injection of scAAV2-P1ND4v2 5.81 X10e9 vg (Med), injection of scAAV2-P1ND4v2 2.4 X10e10vg (High) - Leber's Hereditary Optic Neuropathy
Phase 1CompletedByron Lam282014-07-142025-06-05

Conditions studied

Choroideremia (1)  ·  Optic Atrophy, Hereditary, Leber (1)

Interventions

Matrilin Proteins (1)

Countries

United States (2)

Results publications

PMID 30194931, PMID 24398093, PMID 24457989, PMID 25342621, PMID 26606867, PMID 27631475, PMID 28647203, PMID 35271811, PMID 35344016, PMID 37716450, PMID 38117686

NIH funding

U10EY023558 (1)